Patent · US Active

Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell

US8361982B2 · kind B2 · utility

8Cited by
22References
19Claims
0Family size

Assignees

Inventors

Key dates

Filing dateApr 28, 2010
Grant dateJan 29, 2013
Priority date
Expiry dateMar 17, 2031

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. 1A). Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell. In a further aspect, the invention provides methods for producing siRNA encoding lentivirus where the siRNA activity may interfere with the lentiviral life cycle. In yet a further aspect, the invention provides methods for expression of a small RNA molecule within a cell, such as an siRNA capable of downregulating CCR5, wherein expression of the small RNA molecule is relatively non-cytotoxic to the cell. The invention also includes small RNA molecules, such as an siRNA capable of downregulating CCR5, that are relatively non-cytotoxic to cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.